Literature DB >> 31375974

Determinants of inappropriate implantable cardioverter-defibrillator shocks: the German Device Registry perspective.

Erdal Safak1,2, Lars Eckardt3, Werner Jung4, Hüseyin Ince1,2, Jochen Senges5, Matthias Hochadel5, Christian Perings6, Stefan Spitzer7, Johannes Brachmann8, Karlheinz Seidl9, Hans Ulrich Hink10, Giuseppe D'Ancona11,12.   

Abstract

BACKGROUND: In the present study, we have focused upon rates and clinical determinants of inappropriate shock (IS) after implantable cardioverter-defibrillator (ICD).
METHODS: Data were collected prospectively in the German Device II Registry.
RESULTS: A total of 783 patients were included. Three sub-groups were identified: non-shock (NS) included 725 patients (92.6%), IS 24 (3.1%), and appropriate shock (AS) 34 (4.3%). IS patients were younger (AS 68 (58-77); IS 59 (51-68); NS 66 (56-75) years; p = 0.03), had been mainly referred for primary prophylaxis (AS 42.4%; IS 70.8%; NS 67.3%; p = 0.01), had a higher resting heart rate (AS 70 (63-80); IS 80 (71-98); NS 70 (60-81) BPM; p = 0.003), had more often atrial fibrillation (AF) (AS 14.7%; IS 45.8%; NS 18.8%; p = 0.006), and shorter QRS duration (AS 100 (90-120); IS 95 (90-100); NS 120 (98-150) msec.; p = 0.001). VVI-ICD was more common in IS (AS 64.7%; IS 83.3%; NS 49.8%; p = 0.002). At a follow-up of 18.2 months (75% IQR 13.6-22.4), no deaths were observed in the IS group, one (2.9%) in the AS, and 36 (4.9%) in the NS (p = 0.9). At logistic regression, VVI-ICD implantation was the strongest IS independent determinant (OR 5.0; 95% CI 1.6-15.9; p = 0.004) together with age < 70 years (OR 4.6; CI 1.4-14.7; p = 0.009), AF at time of ICD implantation (OR 3.5; CI 1.3-9.1; p = 0.01), and resting heart rate > 70/min (OR 2.8; CI 1.0-7.3; p = 0.03).
CONCLUSION: In a contemporary setting, some specific conditions such as VVI-ICD, younger age, and faster resting heart rates remain important IS determinants after ICD implantation.

Entities:  

Keywords:  Cardioverter; Defibrillator; Inappropriate; Shock

Mesh:

Year:  2019        PMID: 31375974     DOI: 10.1007/s10840-019-00600-4

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  15 in total

1.  Inappropriate implantable cardioverter-defibrillator shocks: incidence, predictors, and impact on mortality.

Authors:  Johannes B van Rees; C Jan Willem Borleffs; Mihály K de Bie; Theo Stijnen; Lieselot van Erven; Jeroen J Bax; Martin J Schalij
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

2.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure.

Authors:  Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

3.  Dual-chamber versus single-chamber detection enhancements for implantable defibrillator rhythm diagnosis: the detect supraventricular tachycardia study.

Authors:  Paul A Friedman; Robyn L McClelland; William R Bamlet; Helbert Acosta; David Kessler; Thomas M Munger; Neal G Kavesh; Mark Wood; Emile Daoud; Ali Massumi; Claudio Schuger; Stephen Shorofsky; Bruce Wilkoff; Michael Glikson
Journal:  Circulation       Date:  2006-06-12       Impact factor: 29.690

4.  Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT).

Authors:  Dietmar Bänsch; Matthias Antz; Sigrid Boczor; Marius Volkmer; Jürgen Tebbenjohanns; Karlheinz Seidl; Michael Block; Frank Gietzen; Jürgen Berger; Karl Heinz Kuck
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

5.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

6.  Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).

Authors:  Anne-Christine Ruwald; Claudio Schuger; Arthur J Moss; Valentina Kutyifa; Brian Olshansky; Henry Greenberg; David S Cannom; N A Mark Estes; Martin H Ruwald; David T Huang; Helmut Klein; Scott McNitt; Christopher A Beck; Robert Goldstein; Mary W Brown; Josef Kautzner; Morio Shoda; David Wilber; Wojciech Zareba; James P Daubert
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-08-18

7.  Prevention of inappropriate therapy in implantable cardioverter-defibrillators: results of a prospective, randomized study of tachyarrhythmia detection algorithms.

Authors:  Dominic A M J Theuns; A Peter J Klootwijk; Dick M Goedhart; Luc J L M Jordaens
Journal:  J Am Coll Cardiol       Date:  2004-12-21       Impact factor: 24.094

8.  Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact.

Authors:  James P Daubert; Wojciech Zareba; David S Cannom; Scott McNitt; Spencer Z Rosero; Paul Wang; Claudio Schuger; Jonathan S Steinberg; Steven L Higgins; David J Wilber; Helmut Klein; Mark L Andrews; W Jackson Hall; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2008-04-08       Impact factor: 24.094

9.  Amiodarone versus implantable cardioverter-defibrillator:randomized trial in patients with nonischemic dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia--AMIOVIRT.

Authors:  S Adam Strickberger; John D Hummel; Thomas G Bartlett; Howard I Frumin; Claudio D Schuger; Scott L Beau; Cynthia Bitar; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2003-05-21       Impact factor: 24.094

10.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy.

Authors:  Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine
Journal:  N Engl J Med       Date:  2004-05-20       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.